Abstract
H1 nonsedating antihistamines, such as desloratadine, are first-line treatment options for chronic spontaneous urticaria (CSU). However, desloratadine induces various degrees of sedation side effect in CSU patients, and no biomarkers currently exist for predicting the severity of such side effect. Herein, we evaluated the association between HRH1 gene rs901865 polymorphism and the severity of sedation side effect following desloratadine therapy in patients with CSU. We found that 20 of the 114 patients (17.50%) showed sedation side effect after desloratadine treatment, and 3 patients (2.63%) experienced serious sleepiness. The frequency of HRH1 rs901865 G allele was significantly higher in patients who experienced sedation than in patients with rs901865 A allele (pā=ā0.0009). Moreover, patients with the rs901865 G/G genotype suffered a more serious sedation side effect than patients with the rs901865 G/A genotype (pā=ā0.005). These results provide evidence that the HRH1 rs901865 G/G polymorphism is associated with severe sedation side effect after desloratadine treatment. Thus, the HRH1 rs901865 allele may potentially be used as a biomarker for predicting the severity of sedation side effect in patients suffering from CSU and treated with desloratadine.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Maurer M, Weller K, BindslevJensen C, GimĆ©nez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy. 2011;66:317ā30.
Rabelo-FR Daltro-OR, Campos RA. Parameters associated with chronic spontaneous urticaria duration and severity: a systematic review. Int Arch Allergy Immunol. 2013;161:197ā204.
Dressler C, Rosumeck S, Werner RN, Magerl M, Metz M, Maurer M, et al. Executive summary of the methods report for The EAACI/GA2 LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. Allergy. 2018;73:1145ā6.
Izumi N, Mizuguchi H, Umehara H, Ogino S, Fukui H. Evaluation of efficacy and sedative profiles of H1 antihistamines by large-scale surveillance using the visual analogue scale (VAS). Allergol Int. 2008;57:257ā63.
Ng KH, Chong D, Wong CK, Ong HT, Lee CY, Lee BW, et al. Central nervous system side effects of first-and second-generation antihistamines in school children with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled comparative study. Pediatrics. 2004;113:116ā21.
Snidvongs K, Seresirikachorn K, Khattiyawittayakun L, Chitsuthipakorn W. Sedative effects of levocetirizine: a systematic review and meta-analysis of randomized controlled studies. Drugs 2017;77:175ā86.
Kreutner W, Hey JA, Chiu P, Barnett A. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects. Arzneimittelforschung. 2000;50:441ā8.
Johannes R, RuĆ, Anke G, Edwin B, Miller Bruce. Pharmacology and therapeutics. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol. 2001;40:72ā6.
Siebenhaar F, Degener F, Zuberbier T, Martus P, Maurer M. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol. 2009;123:672ā9.
Bachert C, Kuna P, Sanquer F, Ivan P, Dimitrov V, Gorina MM, et al. Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy. 2009;64:158ā65.
Maciel-Guerra H, Penha MĆ, Jorge MFS, LibĆ³rio RDS, Carrijo ACNDA, Parise-Fortes MR, et al. Suppression of wheal and flare in histamine test by the main H1 antihistamines commercialized in Brazil. Bras Dermatol. 2018;93:233ā7.
Hill SJ, Ganellin CR, Timmerman H, Schwartz JC, Shankley NP, Young JM, et al. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharm Rev. 1997;49:253ā8.
Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. Physiol Rev. 2008;88:1183ā241.
Shimamura T, Shiroishi M, Weyand S, Tsujimoto H, Winter G, Katritch V, et al. Structure of the human histamine H1 receptor complex with doxepin. Nature. 2011;475:65ā70.
Panula P, Nuutinen S. The histaminergic network in the brain: basic organization and role in disease. Nat Rev Neurosci. 2013;14:472ā87.
Panula P, Wasowicz K. Action of antiulcer drugs. Science. 1993;262:1454ā5.
Chen C, Hanson E, Watson JW, Lee JS. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos. 2003;31:312ā8.
Baroody F, Proud D, Kagey-Sobotka A, Freidhoff L, Norman PS, Lichtenstein LM, et al. The effects of H1 antihistamines on the early allergic response. Ann Allergy. 1989;63:551ā5.
Parmentier R, Zhao Y, Perier M, Akaoka H, Lintunen M, Hou Y, et al. Role of histamine H1-receptor on behavioral states and wake maintenance during deficiency of a brain activating system: a study using a knockout mouse model. Neuropharmacology. 2016;106:20ā34.
Tiwari AK, Zhang D, Pouget JG, Zai CC, Chowdhury NI, Brandl EJ, et al. Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain. World J Biol Psychiatry. 2016;15:1ā9.
Anvari S, Vyhlidal CA, Dai H, Jones BL. Genetic variation along the histamine pathway in children with allergic versus nonallergic asthma. Am J Respir Cell Mol Biol. 2015;53:802ā9.
Raje N1, Vyhlidal CA, Dai H, Jones BL. Genetic variation within the histamine pathway among patients with asthma-a pilot study. J Asthma. 2015;52:353ā62.
Li P, Wei MJ, Zhang ZY, Yin SJ, Wang X, Lou YQ, et al. Effects of UGT1A1, CYP3A5 and ABCB1 genetic variants on pharmacokinetics of antihistamine drug mizolastine in chinese healthy volunteers. Basic Clin Pharm Toxicol. 2018;123:464ā73.
Yan S, Chen W, Wen S, Zhu W, Guo A, Chen X, et al. Influence of component 5a receptor 1 (C5AR1)-1330T/G polymorphism on nonsedating H1-antihistamines therapy in Chinese patients with chronic spontaneous urticaria. J Dermatol Sci. 2014;76:240ā5.
Guo A, Zhu W, Zhang C, Wen S, Chen X, Chen M, et al. Association of FCER1A genetic polymorphisms with risk for chronic spontaneous urticaria and efficacy of nonsedating H1-antihistamines in Chinese patients. Arch Dermatol Res. 2015;307:183ā90.
Li J, Guo A, Chen W, Bin L, He Y, Zhu W, et al. Association of ORAI1 gene polymorphisms with chronic spontaneous urticaria and the efficacy of the nonsedating H1 antihistamine desloratadine. J Allergy Clin Immunol. 2017;139:1386ā8.
Parmentier R, Ohtsu H, Djebbara-Hannas Z, Valatx JL, Watanabe T, Lin JS. Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep-wake control. Neurosci. 2002;22:7695ā711.
Zhou MH, Zheng H, Si H, Jin Y, Peng JM, He L, et al. Stromal interaction molecule 1 (STIM1) and Orai1 mediate histamine-evoked calcium entry and nuclear factor of activated T-cells (NFAT) signaling in human umbilical vein endothelial cells. J Biol Chem. 2014;17:29446ā56. 289
Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14:540ā5.
Wright C, Shin JH, Rajpurohit A, Deep-Soboslay A, Collado-Torres L, Brandon NJ, et al. Altered expression of histamine signaling genes in autism spectrum disorder. Transl Psychiatry 2017;9:e1126.
Solismaa A, Kampman O, LyytikƤinen LP, SeppƤlƤ N4, Viikki M, Mononen N, et al. Histaminergic gene polymorphisms associated with sedation in clozapine-treated patients. Eur Neuropsychopharmacol. 2017;27:442ā9.
Vehof J, Risselada AJ, Al Hadithy AF, Burger H, Snieder H, Wilffert B, et al. Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication. Psychopharmacology. 2011;216:257ā65.
Godlewska BR, Olajossy-Hilkesberger L, Olajossy M, Limon J, Landowski J. Polymorphisms of the histamine receptor (H1HR) gene are not associated with olanzapine-induced weight gain. J Clin Psychopharmacol. 2013;33:436ā7.
Acknowledgements
This work was supported by grants from the National Natural Science Foundation of China (grant Nos. 81430075 and 81225013 to Chen X.; grant No. 81673065 to Jie Li), Science and Technology Project of Hunan Province (2014SK3108 to Jie Li), Science and Technology Committee of Haidian District (C4WNX-001 to Juan Li).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisherās note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Li, J., Chen, W., Peng, C. et al. Human H1 receptor (HRH1) gene polymorphism is associated with the severity of side effects after desloratadine treatment in Chinese patients with chronic spontaneous uticaria. Pharmacogenomics J 20, 87ā93 (2020). https://doi.org/10.1038/s41397-019-0094-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41397-019-0094-0